Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

March 29, 2012 updated by: Green Cross Corporation

Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A

The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

71

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hemophilia A patients at least 12 years of age
  • At least 150 treatment exposure-days to previous FVIII products
  • FVIII≤2% at screening or diagnosis (FVIII≤1% for PK study)
  • CD4 Lympocyte cell count>400/㎕
  • Patients willing to cooperate for the study
  • Patient's or legal guardian's consent to participate in the study

Exclusion Criteria:

  • FVIII inhibitor(neutralizing antibody to FVIII)≥0.6 Bethesda Units
  • Coagulation disorders other than hemophilia A (e.g. Idiopathic Thrombocytopenic Purpura, von Willebrand Disease)
  • Platelet count≤100,000㎣
  • Subjects with clinical evidence of symptomatic HIV disease regardless of HIV-seroposive/seronegative
  • Subjects with rFVIII antibody, mouse IgG antibody, or CHO antibody
  • Creatinine levels more than 2 times of reference rage, GOT and GPT levels more than 3 times of reference range, diabetes mellitus or other metabolic disorder
  • Subjects with diastolic blood pressure≥100mmHg not controlled with antihypertensive medications
  • Anemia(hemoglobin<12g/dL)
  • Subjects with severe or life-threatening bleeding just before entry into the trial
  • Subjects with a history of treatment failure due to formation of inhibitor to FVIII
  • Subjects with a history of severe hypersensitive reactions to FVIII concentrate
  • Subjects requiring pre-medication for FVIII infusion(e.g. antihistamines, etc)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: test drug
GreenGene
Drug: GreenGene
Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physician's assessment of hemostatic effect for on-demand treatment
Time Frame: 12 months
Category: Exellent, Good, Moderate, None
12 months
Hemostatic effect for major bleeding
Time Frame: up to 1 year
Category: Exellent, Good, Moderate, None
up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
consumption amount of test drug
Time Frame: up to 12 month or 100 exposure days
up to 12 month or 100 exposure days
Subject's self assessment of treatment
Time Frame: 12 months
Category: Exellent, Good, Moderate, None
12 months
FVIII Recovery(%)
Time Frame: every 3 months
every 3 months
FVIII inhibitor incidence rate
Time Frame: every 3 months
every 3 months
The number of adverse events
Time Frame: up to 1 year
up to 1 year
Surgery study: prohylactic effects
Time Frame: up to 1 year
Category: Exellent, Good, Moderate, None
up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Green Cross Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2004

Primary Completion (Actual)

September 1, 2006

Study Completion (Actual)

September 1, 2006

Study Registration Dates

First Submitted

March 22, 2012

First Submitted That Met QC Criteria

March 29, 2012

First Posted (Estimate)

April 2, 2012

Study Record Updates

Last Update Posted (Estimate)

April 2, 2012

Last Update Submitted That Met QC Criteria

March 29, 2012

Last Verified

March 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GC8AIII

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemophilia A

Clinical Trials on GreenGene

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe